We are pleased to announce our latest news to you.

Nothing about patients without patients. This is how admedicum works. And so we also produced a new video that deals with the decision-making situation of patients who can participate in a clinical study.


LS Academy and admedicum Business for Patients are pleased to invite you to the Pegasus Networking Reception on Monday 2 March from 18.00-20.00. This event will feature an interactive parliamentary-style debate moderated by Paola Kruger, EUPATI Italy, and Roger Legtenberg, Upstrong, former CEO of PSR Clinical Research, where participants will be guided through a lively debate of current issues in patient engagement in research and development.

We are delighted to announce Roger Legtenberg as a new independent Expert Partner to our team! Roger, who runs his own consultant firm Upstrong and who is based in the Netherlands, brings significant expertise in regard to clinical development and operations, especially in the rare diseases, and the involvement of patients in the design and recruitment of clinical trials.

Topics include: Why Patient Engagement, Patient Landscape, Legal and Behavioural Compliance, Contacting Patients and Patient Organisations, Collaboration and Co-Creation, Performance Measurement. You will learn how to initiate and manage collaboration with patients in the e-Learning programme. 

An indispensable prerequisite for the implementation of patient engagement within the company is to know first of all what patients want. This includes their needs, desires, priorities and preferences. This is increasingly recognized in the pharmaceutical industry. In major publications on collaboration with patients, the European (EFPIA) and many national industry associations as e.g. the German Pharmaceutical Industry Association (BPI) or the Association of the British Pharmaceutical Industry (ABPI) have assigned great importance to this question.

What these services have in common is that they will only have a patient impact if they provide solutions to real problems. This can only be achieved if a detailed understanding of the patient journey (treatment path) and different patient typologies is given. Such understanding cannot be obtained if companies try to work only with physicians (whose role remains important), since physicians don’t live with the disease and often cannot know or judge why certain decisions are made by patients in daily life. The patient journey and what is relevant to them can only be systematically determined when it is done together with affected patients.

admedicum webinar: Enhancing clinical trial recruitment: successful industry strategies using patient engagement took place on 6 November 2019. We explored how the industry can engage with patients to support clinical trial recruitment rather than just taking the classic method of opening more trial sites. 

admedicum, in collaboration with WAPO, Lupin Pharmaceuticals held a PEGASUS Patient Engagement Networking event on 10 December in Leiden. We hosted around 40 attendees from patient organizations, interested patients, companies, and other stakeholders in healthcare in an informal networking event over drinks.


A study design that is acceptable to patients may not only be important for the actual relevance of a clinical study, but also for the speed of recruitment and protocol-compliant retention during the study. Patient involvement can therefore directly influence time to market.

admedicum webinar: Successful industry strategies for implementing Federated European Registries. We explored how the industry can engage with patients to support the formation of strong patient organizations and how that step is important to the creation of federate patient registries. Watch the full recording now.

Search the news